LOS ANGELES – Armata Pharmaceuticals, Inc. a clinical-stage biotechnology company, has officially commissioned its new state-of-the-art cGMP (current Good Manufacturing Practice) manufacturing facility in Los Angeles. The 56,000-square-foot plant is a critical asset that will supply the company’s proprietary bacteriophage therapies for upcoming clinical trials and future commercial use.
The facility’s activation marks a pivotal step for Armata as it advances its pipeline of innovative treatments designed to combat the growing global threat of antibiotic-resistant bacterial infections.
A Fully Integrated Domestic Manufacturing Hub
The new facility is designed to be a comprehensive, domestic manufacturing center. It features 10,000 square feet of cGMP clean rooms an automated fill-and-finish suite, and dedicated quality control and R&D laboratories. This allows Armata to control the entire production process “from procurement of active pharmaceutical ingredients through fill and finish activities.”
The U.S. Food and Drug Administration (FDA) has been notified that production has commenced, with the company reporting that full production runs have been completed without issues.
Fueling Clinical Trials and Future Commercial Supply
The primary initial purpose of the facility is to manufacture Armata’s high-purity phage cocktails to support its clinical development program. This includes supplying a potential pivotal Phase 3 trial of its candidate, AP-SA02, which is planned for 2026, pending FDA review.
The site is also strategically designed with the capacity to support future commercial-scale production and explore contract manufacturing opportunities for other companies, providing a potential future revenue stream.
A Milestone Amidst Positive Clinical News
“The full commissioning of our manufacturing facility represents a key milestone for Armata,” said Dr. Deborah Birx, Chief Executive Officer of Armata.
The announcement comes on the heels of positive clinical news. The company recently presented Phase 2a data for AP-SA02 at IDWeek 2025, showing an 88% clinical response rate when combined with standard antibiotics, compared to 58% for placebo.